Publications by authors named "Catalin Doru Danaila"
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Jean-Jacques Kiladjian Francisca Ferrer Marin Haifa Kathrin Al-Ali Alberto Alvarez-Larrán Eloise Beggiato Catalin Doru Danaila
Ann Hematol
July 2024
Article Synopsis
- Interferon-based therapies like ropeginterferon alfa-2b are showing promise as potential treatments for essential thrombocythemia (ET), which current therapies don't modify or improve disease progression.
- Ropeginterferon alfa-2b has been effective in treating polycythemia vera (PV) and could similarly benefit ET patients who can't tolerate or are resistant to existing treatments.
- The ongoing ROP-ET trial aims to evaluate its effectiveness over three years, focusing on patient responses, quality of life, and safety, providing crucial data for treatment options in this underserved group.
Blastic plasmacytoid dendritic cell neoplasms (BPDCNs) are extremely rare and aggressive hematological malignancies that derive from precursors of plasmacytoid dendritic cells (pDC) and frequently involve skin lesions and bone marrow infiltration. They mostly affect the elderly population and the prognosis is poor with the therapeutic choices currently available. Diagnosis is made with the help of tools such as immunohistochemistry and flow cytometry.
View Article and Find Full Text PDF